Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel versus docetaxel plus prednisone in chemotherapy-naive metastatic castration-resistant prostate cancer
2010-022064-12Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cabazitaxel, docetaxel and prednisone in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by Sanofi. Primary endpoint: Overall survival. Started Jan 2011; status: completed.
02
Drugs
cabazitaxeldocetaxelprednisone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2010-022064-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022064-12.